UnknownPhase 1

Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration

Japan6 participantsStarted 2017-11-15

Plain-language summary

The purpose of this study is to determine the safety and effectiveness of intracoronary infusion of autologous cardiac stem cells in patients with ischemic cardiomyopathy.

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult with ability to provide informed consent. * Left ventricular ejection fraction less than 40% as evidenced by echocardiogram. * Scheduled for elective surgical revascularization within 2 months. Exclusion Criteria: * Positive for HBs-Ag, HCV-Ab, HIV-Ab, or tests for syphilis. * Diabetic HbA1c greater than 8.5%. * Pregnant women. * Scheduled for additional interventions including ventriculoplasty.

What they're measuring

Monitoring adverse events

Timeframe: 2 years

Trial details

NCT IDNCT03351400

SponsorSakakibara Heart Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-03

View on ClinicalTrials.gov More Chronic Heart Failure trials